Osteoporosis, Postmenopausal
Conditions
Brief summary
This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal women who previously received HRT.
Interventions
DRUGRisedronate
DRUGRaloxifene
OTHERPlacebo
Sponsors
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
No minimum to 65 Years
Healthy volunteers
No
Inclusion criteria
* Postmenopausal, ambulatory females, postmenopausal defined as the absence of menses for at least 12 continuous months) * In general good health as determined by medical history, physical examination, and laboratory tests * LS spine BMD T-score between -1.0 and -2.4, inclusive * At least one analyzable BMD site at both the hip (left or right) and LS spine (at least 3 measurable lumbar spine vertebrae, without fracture or sufficient degenerative disease) * Currently receiving no medications for the treatment or prevention of osteoporosis * Had been on continuous HRT for at least 1 year prior to enrollment. The HRT must have ended within 18 months prior to the baseline visit, and the subject must have been off HRT medication for at least 3 months at the time of baseline visit * Subjects rendered menopausal by surgical procedures between the ages of 55 and 65 years
Exclusion criteria
* A history of cancer within 10 years prior to entry into the study, except for relatively benign and cured skin cancers such as basal and squamous cell carcinoma * A history of hyperparathyroidism, hyperthyroidism, osteomalacia, or other metabolic bone disease within one year prior to enrollment * Any condition or disease that may interfere with the evaluation of at least 3 lumbar vertebrae (not necessarily contiguous), determined in a screening radiograph by a radiologist at the central facility (e.g., confluent aortic calcifications, severe osteoarthritis, spinal fusion, lumbar spine fractures) * Evidence of clinically significant organic or psychiatric disease on history or physical examination, which in the opinion of the investigator would prevent the patient from completing the study * Markedly abnormal pretreatment laboratory finds that, in the opinion of the investigator, would prevent the patient from completing the study * A history of using any of the following medications prior to starting study: * Any bisphosphonate therapy * Selective estrogen receptor modulators (SERMs) * Parathyroid hormone * Fluorides * Calcitonin * Calcitriol (\>1.5 mcg/week) * Corticosteroids on a chronic basis for period equal to or greater then 3 months * Received a depot injection of \>10,000 IU Vitamin D in the past 12 months * A history of recurrent nephrolithiasis or a history of one episode of nephrolithiasis within 1 year of study entry * Serum creatinine \>1.6 mg/dl * Unable to sit or stand upright for 30 minutes after taking the morning dose of risedronate * A history of deep vein thrombosis or other coagulation disorders * Severe hepatic insufficiency * A history of hypersensitivity to raloxifene, risedronate, or to drugs with similar chemical structures * Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult * Subjects found to have one or more vertebral fractures after completing thoracic and LS spine films * Subjects who have experienced a low impact fracture related to osteopenia within two years of baseline visit The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare the effects of risedronate and raloxifene on lumbar spine (LS) bone mineral density (BMD) in osteopenic women previously treated with HRT, who discontinued HRT at least 3 months prior to the study but no greater than 18 mos | — |
Secondary
| Measure | Time frame |
|---|---|
| Compare the effects of risedronate, raloxifene, and placebo on BMD of the hip | — |
Countries
United States
Outcome results
None listed